Pharmaceutical Application of Mineral APIs: A Drug-Grade Manufacturing & Sourcing Guide

Introduction: The Same Compound, Two Completely Different Regulatory Lives

Ferrous Sulphate manufactured to Food Chemicals Codex (FCC) standard becomes an ingredient in a dietary iron supplement, regulated as a nutraceutical. The same chemical compound — Ferrous Sulphate — manufactured and documented to pharmacopoeial (USP/BP/IP) standard becomes the active ingredient in an approved anti-anemic drug product, regulated as a pharmaceutical.

Same molecule. Same CAS number. Completely different regulatory pathway, documentation burden, and end-use classification — determined entirely by manufacturing grade and supporting documentation.

This distinction matters because a significant share of confusion in mineral API sourcing comes from treating "pharmaceutical application" and "nutraceutical application" as interchangeable marketing terms rather than what they actually are: distinct regulatory classifications governing the same underlying chemistry.

1. What Makes a Mineral Compound a "Pharmaceutical Application" Ingredient

A mineral compound qualifies for genuine pharmaceutical application when it meets three conditions simultaneously:

• It is manufactured to pharmacopoeial monograph standard — USP (United States Pharmacopeia), BP (British Pharmacopoeia), EP (European Pharmacopoeia), or IP (Indian Pharmacopoeia) — meeting the specific purity, identity, and impurity-limit testing that monograph defines, not the looser FCC food-chemical standard used for nutraceutical ingredients.
• It has an established or supportable therapeutic drug classification — meaning regulatory authorities (FDA, CDSCO, EMA) recognize a defined therapeutic use category for the compound, supported by an approved drug monograph, not merely a "supports wellness" claim.
• It is supplied with documentation a licensed drug manufacturer can reference in their own regulatory filing — Certificate of Analysis against the specific pharmacopoeial monograph, GMP manufacturing evidence aligned with ICH Q7, and stability data supporting the drug product's shelf-life claim.

2. Pharmacopoeial Grade vs Food/Nutraceutical Grade: Why the Distinction Matters

The critical sourcing point: a manufacturer producing both grades is not simply offering "the same product at two price points." The pharmacopoeial-grade version carries a fundamentally different testing, documentation, and regulatory support burden, which is precisely why drug formulators must specify pharma grade explicitly when sourcing, rather than assuming any version of a compound will satisfy a drug product's regulatory filing.

3. India's Pharmaceutical API Export Context (2026 Data)

India's Position in Global Pharmaceutical Supply

India's pharmaceutical industry ranks third globally by volume, with the domestic market valued at approximately $50 billion and pharmaceutical exports reaching $30.5 billion in FY 2024–25, reaching 191 countries, with roughly 50% directed to highly regulated markets including the United States and European Union (Source: Press Information Bureau, Government of India, Economic Survey 2025–26).

API Import Dependency and Policy Response

In FY 2024–25, India imported approximately 200 categories of APIs, bulk drugs, and drug intermediates valued at approximately $4.35 billion, with a single country — China — accounting for approximately 73.7% of that total (Source: PIB, Government of India, Economic Survey 2025–26). This concentration creates supply chain vulnerability for Indian API and formulation manufacturers.

Under India's Production Linked Incentive (PLI) Scheme for bulk drugs, the government has supported domestic manufacturing capacity for Key Starting Materials, Drug Intermediates, and APIs. The PLI Bulk Drugs scheme has already avoided imports worth approximately ₹3,591 crore of APIs, KSMs, and drug intermediates (Source: PIB, Government of India).

Why This Matters for Mineral API Sourcing

As India's drug manufacturing base expands under PLI-supported bulk drug parks, formulators are increasingly seeking pharmacopoeial-grade mineral API suppliers within India's own manufacturing ecosystem. Mineral APIs — iron, calcium, magnesium, sodium, zinc, copper — represent mature, well-established drug substances whose domestic supply chain can meaningfully reduce dependence on imported pharmaceutical-grade raw materials from single-country sources.

4. ICH Q7 in Practice: GMP Expectations Specific to Mineral APIs

ICH Q7 — the internationally harmonized Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients — applies to mineral API manufacturing just as it applies to complex synthetic molecules. Understanding how it applies specifically to inorganic mineral APIs helps buyers evaluate what a supplier's GMP claim actually covers.

Progressive GMP Application Across the Synthesis Route

ICH Q7 establishes that GMP rigor should increase as processing approaches the final API. For mineral APIs, the synthesis route is typically shorter than complex synthetic molecules, meaning GMP expectations apply more uniformly across the manufacturing process compared to a multi-step organic synthesis. Even so, ICH Q7 distinguishes between:

• Starting material qualification — mineral raw materials must meet defined incoming specifications with documented supplier qualification
• In-process controls — critical processing parameters (temperature, reaction time, pH, particle size milling conditions) must be monitored and documented
• API testing — finished API lot must be tested against all pharmacopoeial monograph requirements before release
• Batch record retention — complete batch manufacturing records must be maintained and available for regulatory review

Impurity Control Requirements

For pharmaceutical-grade mineral APIs, impurity control is the area where ICH Q7 adds the most significant requirements beyond general manufacturing practice:

• Related substance and heavy metal impurities: Pharmacopoeial monographs for mineral APIs typically include limits for specific heavy metal contaminants relevant to the production route or raw material source — arsenic, lead, mercury, cadmium. ICH Q3D (Elemental Impurities) guidelines, now referenced in updated pharmacopoeial monographs, add a risk-based approach to elemental impurity control that goes beyond simple heavy metals testing.
• Residual solvent control: Even for inorganic mineral salts, processing solvents used in recrystallization, washing, or drying steps must be controlled and documented to ICH Q3C limits if they fall within the defined solvent classes.
• Microbial limits: For mineral APIs used in parenteral (injectable) drug products, or in products with specific microbial requirements, pharmacopoeial microbial limit testing applies. A Certificate of Analysis for pharmaceutical-grade Zinc Sulphate intended for an injectable multivitamin product carries different microbial testing requirements than the same compound supplied for oral tablet formulation.

Equipment and Facility Standards

ICH Q7 requires that manufacturing equipment used for pharmaceutical-grade API production be:

• Constructed of materials that do not react with, add to, or absorb the API or impurities
• Cleaned and maintained on a documented schedule
• Qualified (installation and operational qualification documented) for critical equipment
• Calibrated on a defined schedule for instruments affecting product quality

For mineral API manufacturers like Shreeji Industries that supply both pharmacopoeial and FCC grades, equipment qualification and cleaning validation become especially important — ensuring that pharma-grade batches cannot be contaminated by residues from food-grade processing, and vice versa.

Change Control and Customer Notification

A frequently underappreciated ICH Q7 requirement in mineral API manufacturing is change control — the formal system governing any change to the manufacturing process, raw material source, equipment, or facility that could affect the API's quality or regulatory compliance status.

5. Pharmacopoeial Monograph Differences: USP vs BP vs EP vs IP

One of the practical complexities buyers face is that the same mineral compound can have meaningfully different monograph requirements across different pharmacopoeias — creating a situation where a batch that passes USP testing may not pass BP or IP testing for the same compound, even though the underlying material is chemically identical.

What Differs Between Pharmacopoeias for the Same Mineral API

• Identity test methods: Different pharmacopoeias sometimes specify different analytical methods for confirming identity — for example, infrared spectroscopy, X-ray diffraction, or wet chemical tests. A Ferrous Fumarate batch characterized by the USP identity test method must be re-tested if the buyer's filing references the BP identity test, as the two may differ procedurally even when both confirm the same compound.
• Assay methods and acceptance criteria: Assay (purity content) acceptance criteria can differ between pharmacopoeias. A mineral compound passing USP's assay specification of a stated purity range may need a separate assay against BP's specification to confirm BP compliance, even if the actual assay value clearly falls within both ranges, because the filing must reference testing against the specific pharmacopoeial method, not simply a measured result.
• Specific impurity limits: The types and limits of permitted impurities can differ between pharmacopoeias, reflecting differences in the regulatory risk assessments underlying each pharmacopoeia. For example, arsenic limit tests, heavy metals tests, and related substance specifications may all carry different permitted levels between USP, BP, EP, and IP monographs for the same compound.
• Dissolution testing (for finished dose context): While dissolution testing is primarily a finished drug product specification rather than API-level, some mineral salt APIs are also tested in finished form against pharmacopoeial dissolution requirements that differ between USP and BP — relevant context for formulators who need to confirm their finished product specification aligns with their target market pharmacopoeia.

Practical Sourcing Implication

A drug formulator exporting finished products to both the US and the UK from India must ensure their mineral API CoA demonstrates compliance with both USP and BP monographs if both markets' filings reference pharmacopoeial compliance. This typically means requesting a dual-monograph Certificate of Analysis from the API supplier, confirming that testing was performed against both relevant monographs rather than just one.

Shreeji Industries manufactures to pharmacopoeial specifications across USP, BP, EP, and IP monographs depending on customer and market requirements, issuing grade-specific Certificates of Analysis confirming which monograph standard the batch was tested against — not a generic "pharmaceutical grade" claim that leaves the monograph reference unspecified.

6. The Mineral APIs Shreeji Industries Manufactures for Pharmaceutical Application

Iron — Established Anti-Anemic Drug Classification

Ferrous Sulphate and Ferrous Fumarate hold long-established status as anti-anemic therapeutic agents under multiple pharmacopoeial monographs — USP, BP, and IP all carry independent monographs for these compounds — used in licensed drug products specifically indicated for iron-deficiency anemia treatment.

Shreeji supplies: Dried Ferrous Sulphate, Ferrous Fumarate, Ferrous Gluconate, Ferrous Bis Glycinate — multiple forms with distinct solubility, taste, and stability profiles suited to different finished oral drug formulations (tablet, syrup, chewable).

Calcium — Antacid and Therapeutic Calcium Replacement Drug Classification

Calcium carbonate and calcium phosphate salts hold established drug monograph status as antacid agents and as therapeutic calcium replacement products for diagnosed calcium deficiency — both recognized pharmaceutical drug categories with long-standing OTC and Rx monograph history.

Shreeji supplies: Di-Calcium Phosphate (Dihydrate and Anhydrous), Tri-Calcium Phosphate, Calcium Gluconate, Calcium Citrate, Calcium Citrate Malate — varying in elemental calcium content, solubility, and compressibility for different oral solid dosage forms.

Magnesium — Laxative and Antacid Drug Classification

Magnesium Oxide and Magnesium Hydroxide hold long-established pharmacopoeial drug status as both laxative agents and antacid agents — among the oldest recognized therapeutic mineral drug classes, still referenced in current pharmacopoeial monographs globally.

Shreeji supplies: Light and Heavy Magnesium Oxide FCC (both manufacturable to pharmacopoeial specification), Magnesium Sulphate Anhydrous and Heptahydrate — the distinction between light and heavy oxide grades reflecting different bulk density and surface area relevant to finished tablet formulation performance.

Sodium — Electrolyte Replacement and Oral Rehydration Drug Classification

Sodium Chloride holds established pharmaceutical status as an electrolyte replacement agent, including as a core component of Oral Rehydration Salts (ORS) formulations — the WHO/UNICEF-recommended treatment for dehydration.

Shreeji supplies: Sodium Chloride, Sodium Citrate Dihydrate IP, Sodium Iron EDTA FCC — where Sodium Citrate specifically holds IP monograph compliance for the Indian pharmaceutical market and serves as an alkalinizing agent/electrolyte in pharmaceutical formulations.

Zinc — WHO-Recognized Therapeutic Supplementation Classification

Zinc Sulphate holds recognized therapeutic status, including WHO/UNICEF joint guidance recommending zinc supplementation alongside ORS in pediatric diarrheal disease management — a globally recognized pharmaceutical application distinct from general nutraceutical use.

Shreeji supplies: Zinc Sulphate Monohydrate and Heptahydrate (distinct hydration states with different elemental zinc percentages per gram), Zinc Oxide FCC, Zinc Gluconate, Zinc Bis Glycinate — providing formulators choice of form based on solubility, stability, and taste requirements.

Copper — Trace Element Therapeutic Application

Copper compounds are recognized for therapeutic trace-element application in clinically supervised contexts — including parenteral (intravenous) nutrition formulations where copper deficiency must be corrected under medical supervision.

Shreeji supplies: Copper Sulphate Anhydrous FCC, Copper Sulphate Pentahydrate, Copper Gluconate USP — with USP grade copper gluconate specifically positioned for formulations requiring pharmacopoeial compliance.

Halquinol — Correctly Classified as Veterinary Pharmaceutical Application

7. Master Reference Table: Established Drug Classifications by Compound

8. Drug Formulator's Supplier Audit Checklist

This section addresses what a drug formulator's quality team actually evaluates when qualifying a mineral API supplier — going beyond the standard CoA request to the structured vendor audit process that regulated drug manufacturers operate under.

Documentation Review (Pre-Audit)

Before conducting a physical or virtual facility audit, a qualified drug formulator's procurement and quality teams typically conduct a documentation review:

• Quality Manual: Does the supplier maintain a documented Quality Management System covering API manufacturing? Is it formally written and version-controlled?
• Site Master File or equivalent: A document describing the manufacturing facility, its scope, GMP compliance status, and regulatory inspection history
• Pharmacopoeial CoA samples: Certificates of Analysis from multiple recent batches, allowing assessment of batch-to-batch consistency in assay value and impurity profile rather than a single "best batch" sample
• Regulatory inspection history: Has the facility been inspected by FDA, EMA, CDSCO, or equivalent authority? What were the outcomes? Were deficiency observations raised, and what was the corrective action response?
• Deviation and CAPA records (summary): Evidence that the facility identifies, investigates, and corrects manufacturing deviations — a functional CAPA system is a meaningful indicator of quality culture

Manufacturing Process Evaluation

During audit (physical or virtual), specific manufacturing process elements are assessed:

• Raw material specification and incoming testing: Are incoming mineral raw materials tested against defined specifications before use? Who are the raw material suppliers, and are they qualified?
• In-process monitoring: Are critical process parameters (particle size, moisture content, reaction completion, purity at intermediate stages) monitored and documented during production?
• Contamination controls: For a supplier manufacturing both pharmacopoeial-grade and food-grade products in the same facility, are there adequate controls preventing cross-contamination between grade levels?
• Water system: What is the quality of process water used in manufacturing? Is it monitored and controlled to appropriate standards for pharmaceutical manufacturing?

Change Control and Notification Capability

A functioning change control system is one of the clearest indicators of ICH Q7-aligned manufacturing maturity:

• Does the supplier have a formal change control procedure? Changes to raw material sources, manufacturing processes, equipment, or facility should be evaluated, documented, and communicated to affected customers before implementation
• What is the advance notice period for planned changes? Regulated drug formulators typically need 6–12 months' advance notice of process changes to assess regulatory impact and file variations if necessary
• What is the supplier's track record of change notifications? Reference checks with existing customers reveal whether formal change notification procedures are actually followed in practice

Analytical Method Validation

For pharmaceutical-grade mineral APIs, the analytical methods used to generate the Certificate of Analysis should themselves be validated:

• Are methods referenced to pharmacopoeial procedures? Compendial methods (USP/BP general chapters) are pre-validated; non-compendial methods require independent validation documentation
• Is HPLC or ICP-MS used for heavy metal testing? Modern heavy metals testing by inductively coupled plasma mass spectrometry (ICP-MS) aligns with ICH Q3D elemental impurity requirements; older colorimetric methods may not provide the sensitivity modern pharmacopoeia updates expect
• Are method validation reports available on request? A supplier able to provide validation documentation for their primary assay and impurity methods demonstrates analytical rigor beyond routine testing

9. Common Misconceptions About Pharmaceutical Application Claims

Misconception #1: "Pharmaceutical" and "Nutraceutical" Application Are the Same Marketing Claim

Reality: They represent genuinely different regulatory classifications with different monograph standards, documentation requirements, and end-use drug categories. A supplier should specify which grade and which application a given product batch supports rather than using both terms interchangeably.

Misconception #2: Any Antimicrobial Compound in a Portfolio Is a Human Pharmaceutical

Reality: As the Halquinol example demonstrates, a compound can have genuine, well-documented antimicrobial activity while holding an established regulatory classification exclusively for veterinary or feed-additive use. Buyers and content describing such compounds should verify and state the correct regulatory use category.

Misconception #3: One CoA Covers All Pharmacopoeial Standards

Reality: A Certificate of Analysis generated against USP specifications does not automatically confirm BP or IP compliance for the same compound. Each pharmacopoeial standard may have different test methods, acceptance criteria, and impurity limits. Multi-market drug formulators should request dual or multi-monograph CoA confirmation explicitly.

Misconception #4: Established Drug Classification Means No Further Regulatory Work Is Needed

Reality: Even when a compound (such as Ferrous Sulphate as an anti-anemic agent) holds long-established drug classification, a specific finished drug product still requires its own regulatory approval (ANDA, drug license, or equivalent) referencing the specific API source and specification.

Misconception #5: Switching Mineral API Suppliers Is a Simple Commercial Decision

Reality: If a mineral API is referenced in a drug formulator's ANDA, drug license, or DMF filing, switching API suppliers may constitute a manufacturing process change requiring regulatory notification or variation filing. This makes mineral API sourcing — even for seemingly simple inorganic compounds — a regulatory decision with real timeline implications, not solely a procurement comparison.

10. Frequently Asked Questions

What's the difference between pharmaceutical-grade and nutraceutical-grade for the same mineral compound?

Pharmaceutical-grade mineral APIs are manufactured to pharmacopoeial monograph standards (USP/BP/EP/IP) and intended for licensed drug products with established therapeutic drug classifications. Nutraceutical-grade versions are typically manufactured to FCC standard for dietary supplements under food/supplement regulatory frameworks. The underlying chemical compound can be identical, but testing rigor, impurity limits, documentation, and regulatory pathway differ substantially.

Why do different pharmacopoeias have different tests for the same mineral compound?

Different national pharmacopoeias were developed independently, reflecting different analytical traditions, risk assessments, and available testing technologies at the time their monographs were written. While harmonization under ICH has aligned many requirements, differences in specific impurity limits, identity test methods, and assay procedures remain between USP, BP, EP, and IP for the same compound. Drug formulators exporting to multiple markets must confirm which pharmacopoeial standard their filing references and request testing specifically against that standard.

Is Halquinol used in human pharmaceutical products?

No. Halquinol's established regulatory classification, confirmed by veterinary regulatory authorities including Australia's APVMA, is as a veterinary antimicrobial — specifically a poultry feed additive and growth promoter/anti-diarrheal agent for pigs. It is not classified for human pharmaceutical drug use. Its growing importance is in antibiotic-free livestock production programs, not human formulation.

Why does zinc sulphate have a specific WHO-recognized pharmaceutical application?

The World Health Organization and UNICEF issued joint clinical guidance recommending zinc supplementation alongside Oral Rehydration Salts for managing diarrheal disease in children, based on clinical evidence of reduced disease duration and severity. This represents a globally recognized therapeutic application of zinc sulphate that goes beyond general dietary use and is cited in national treatment guidelines across developing markets where diarrheal disease remains a significant health burden.

What ICH guidelines are most relevant to mineral API manufacturing?

ICH Q7 (GMP for APIs) is the primary manufacturing standard. ICH Q3D (Elemental Impurities) is increasingly relevant as pharmacopoeial monographs update to reference elemental impurity testing by ICP-MS rather than older colorimetric heavy metals tests. ICH Q3C (Residual Solvents) applies where organic solvents are used in mineral API processing steps such as recrystallization or washing.

Can the same facility produce both pharma-grade and FCC-grade mineral compounds?

Yes, this is common practice including at Shreeji Industries. What matters for buyers is requesting and verifying the Certificate of Analysis and documentation specific to the grade they require, and during supplier audit, confirming that adequate contamination controls exist between grade levels — particularly cleaning procedures and equipment dedication policies.

What documentation should accompany a pharma-grade mineral API shipment?

At minimum: a batch-specific Certificate of Analysis tested against the specific pharmacopoeial monograph (USP/BP/EP/IP) the buyer's filing references, confirming assay, related substances, heavy metals or elemental impurities, and microbial limits. Additionally: a current Material Safety Data Sheet, GMP manufacturing certification, and, where the intermediate is referenced in a regulatory filing, supporting manufacturing process documentation the buyer can include in their own DMF or drug license submission.